Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.

Trial Details

NCT ID
NCT06433609
Phase
PHASE2
Sponsor
Beijing GoBroad Hospital
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • SHR-A1811
  • SHR-A1921
  • Adebrelimab
  • SHR-A2102
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • 18 years to 75 years old (including boundary values);
  • ECOG PS Score: 0\~1;
  • Histologically or cytologically confirmed HER2-negative advanced breast cancer;
  • Disease progression after prior ≥1 line of systemic therapy; if HR-positive, prior CDK4/6 inhibitor is necessary;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →